By 2030, it is anticipated that the Philippines infectious disease therapeutics market will reach a value of $385.2 Mn from $263.71 Mn in 2022, growing at a CAGR of 4.9% during 2022-2030. The Infectious Disease Therapeutics in the Philippines is dominated by a few domestic pharmaceutical companies such as Glovax Biotech, United Laboratories and Pharex Health Corporation. The Infectious Disease Therapeutics market in the Philippines is segmented into different therapeutic areas and different diseases type. The major factors affecting the Philippines' infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of the Philippines.
By 2030, it is anticipated that the Philippines infectious disease therapeutics market will reach a value of $385.2 Mn from $263.71 Mn in 2022, growing at a CAGR of 4.9% during 2022-2030.
The Philippines is a low-middle-income developing country in Southeast Asia in the western Pacific Ocean. According to the World Factbook, the Philippines is particularly susceptible to infectious diseases. Bacterial diarrhoea, hepatitis A, and typhoid fever are examples of food or waterborne infections. Leptospirosis is a water-borne infection that is common in the Philippines.
The Philippines is also involved in vaccine development, with the Ministry of Health and the Research Institute for Tropical Medicine (RITM) in charge of vaccine development and delivery. The RITM manufactures a variety of vaccinations, including those against polio, measles, and dengue fever. The Philippines' government spends 5.1% of its GDP on healthcare.
Market Growth Drivers Analysis
The Philippines has a high prevalence of infectious diseases, with tuberculosis, malaria, and dengue fever being the most frequent. The development and availability of infectious illness treatments are critical for preventing and treating these ailments. In the Philippines, the situation is extremely challenging - the WHO estimates that in 2019, up to 1 Mn Filipinos had active TB, the third highest frequency in the world. Every day, over 70 people in the country die as a result of this completely treatable condition. The Philippines' Business Process Outsourcing (BPO) industry is thriving. These aspects could boost Philippine's infectious disease therapeutics market.
Market Restraints
According to the Philippine National Health Research System (PNHRS), tuberculosis (TB) is most prevalent among the urban poor, who frequently lack access to health care. Although the Filipino government has taken attempts to reduce the cost of TB treatment for low-income households through its aforementioned National Tuberculosis Program, 2022 research revealed that 42 % of TB households were still experiencing "catastrophic expenditures" linked with the condition. Certain infectious diseases may have a limited study focus, notably those that primarily afflict poor nations or have relatively low incidence rates in the Philippines. The Philippines has high levels of income disparity and underemployment, which leads to expatriation. These factors may deter new entrants into the Philippines infectious disease therapeutics market.
Key Players
February 2023: Tanco-led Maestro Holdings and Reliance United, a subsidiary of United Laboratories (Unilab), the leading pharmaceutical company in the Philippines and Southeast Asia, have formed a partnership that will provide access to Reliance United’s full-service Healthfirst Clinic to members of the pioneering health maintenance organisation PhilCare. The collaboration validates the two companies' dedication to providing the greatest healthcare services to their clients and solidifies their position as two of the most active institutions in the country's healthcare market.
The Food and Drug Administration regulates infectious illness medicines in the Philippines (FDA). Through the Philippine Health Insurance Corporation, the government offers subsidised healthcare services to the populace, including treatments for infectious diseases (PhilHealth). PhilHealth is responsible for overseeing the national health insurance programme, which offers coverage for a range of healthcare services, including medicines and treatments for infectious diseases.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Philippines infectious disease therapeutics market will reach a value of $385.2 Mn from $263.71 Mn in 2022, growing at a CAGR of 4.9% during 2022-2030.
In the Philippines, the regulation of infectious disease therapeutics is overseen by the Food and Drug Administration (FDA). The government provides subsidized healthcare services to the population, including treatments for infectious diseases, through the Philippine Health Insurance Corporation (PhilHealth).
The Infectious Disease Therapeutics in the Philippines is dominated by a few domestic pharmaceutical companies such as Glovax Biotech, United Laboratories and Pharex Health Corporation.